• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> compound, pharmaceutical composition, and methods for inhibiting a soluble epoxide hydrolase, the progression of nephropathy, and the obstruction of obstructive pulmonary disease, an interstitial lung disease or asthma in a patient, to treat soluble epoxide hydrolase-modulated diseases, to reduce renal deterioration, blood pressure, vascular inflammation, renal inflammation in a patient, and the formation of a biologically active diol, to regulate endothelial cell function in a patient, to decrease endothelial cell inflammation in a patient, and to monitor the activity of a soluble epoxide hydrolase

compound, pharmaceutical composition, and methods for inhibiting a soluble epoxide hydrolase, the progression of nephropathy, and the obstruction of obstructive pulmonary disease, an interstitial lung disease or asthma in a patient, to treat soluble epoxide hydrolase-modulated diseases, to reduce renal deterioration, blood pressure, vascular inflammation, renal inflammation in a patient, and the formation of a biologically active diol, to regulate endothelial cell function in a patient, to decrease endothelial cell inflammation in a patient, and to monitor the activity of a soluble epoxide hydrolase

机译：化合物，药物组合物和用于抑制可溶性环氧化物水解酶，肾病的进展以及阻塞患者的阻塞性肺疾病，间质性肺病或哮喘的方法，以治疗可溶性环氧化物水解酶调节的疾病，以减少肾脏恶化，血压，血管炎症，患者的肾脏炎症以及生物活性二醇的形成，以调节患者的内皮细胞功能，减少患者的内皮细胞炎症，并监测可溶性环氧化物水解酶的活性

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR INHIBITING A SOLUBLE HYDROLASE EPÁXIDE, THE PROGRESSION OF NEPHROPATHY, AND THE PROGRESSION OF OBSTRUCTIVE PULMONARY DISEASE, AN INTERSTITIAL LUNG DISEASE IN A PATENTED, PHARMACEUTICAL, PHARMACEUTICAL, PHARMACEUTICAL, PHARMACEUTICAL, PHARMACEUTICAL KIDNEY DETERIORATION, BLOOD PRESSURE, VASCULAR INFLAMMATION, KIDNEY INFLAMMATION IN A PATIENT, AND THE FORMATION OF A BIOLOGICALLY ACTIVE DIOL, TO REGULATE ENDOTHELIAL CELL FUNCTION IN A PATIENT, INTO A LOT OF PEOPLE, IN LAMINATION MONITOR THE ACTIVITY OF A SOLUBLE HYDROLASE EPAXIDE. Compounds of formula (I) where R ^ 1 ^ is a selected member of the group consisting of C ~ 1 ~ -C ~ 8 ~ alkyl, C ~ 0 ~ -C ~ 8 ~ arylalkyl, C ~ 3 ~ -C cycloalkyl ~ 12 ~ and heterocyclyl, Y ^ 1 ^ is selected from the group consisting of a bond, C (R ^ 5 ^) ~ 2 ~, NR ^ 5 ^ and O; Y ^ 2 ^ is selected from the group consisting of a bond, NR ^ 5 ^ and O; each R ^ 2 ^, R ^ 3 ^ and R ^ 5 ^ is independently selected from the group consisting of H, alkyl and COR ^ 6 ^; A is heterocyclyl, optionally substituted with 1 to 2 R 7 7 substituents; L is selected from the group consisting of a direct bond, C ~ 1 ~ -C ~ 12 ~ alkylene, C ~ 1 ~ -C ~ 12 ~ heteroalkylene, C ~ 3 ~ -C ~ 6 ~ cycloalkylene, arylene, heteroarylene, - CO-, -SO and -Se-; R ^ 4 ^ is selected from the group consisting of H, C ~ 1 ~ -C ~ 8 ~ alkyl, C ~ 2 ~ -C ~ 6 ~ alkenyl, C ~ 2 ~ -C ~ 6 ~ alkynyl, C ~ 1 heteroalkyl ~ -C ~ 8 ~, C ~ 0 ~ -C ~ 8 ~ arylalkyl, C ~ 3 ~ C ~ 12 ~ cycloalkyl and heterocyclyl are claimed. The compounds are inhibitors of soluble epoxide hydrolase (sEH) and useful for the treatment of hypertension, inflammation, adult respiratory distress syndrome; diabetic complications; end-stage kidney disease; Raynaud's syndrome and arthritis.
机译：专利，药物，药物，药物，药物，药物，药物，药物，药物，药物和药物，血管炎症，患者肾脏炎症以及生物活性二元醇的形成，以调节患者中的内皮细胞功能，使大量人在覆膜过程中监测可溶性水解酶的活性。式（I）的化合物，其中R ^ 1 ^是C〜1〜-C〜8〜烷基，C〜0〜-C〜8〜芳烷基，C〜3〜-C环烷基〜 12〜和杂环基，Y ^ 1 ^选自由键，C（R ^ 5 ^）〜2〜，NR ^ 5 ^和O组成的组; Y ^ 2 ^选自由键，NR ^ 5 ^和O组成的组;每个R ^ 2 ^，R ^ 3 ^和R ^ 5 ^独立地选自H，烷基和COR ^ 6 ^; A是杂环基，任选地被1-2个R 7 7取代基取代; L选自由以下组成的组：直接键，C〜1〜-C〜12〜亚烷基，C〜1〜-C〜12〜杂亚烷基，C〜3〜-C〜6〜环亚烷基，亚芳基，杂亚芳基，- CO-，-SO和-Se-; R ^ 4 ^选自H，C〜1〜-C〜8〜烷基，C〜2〜-C〜6〜烯基，C〜2〜-C〜6〜炔基，C〜1杂烷基要求保护的是〜-C〜8〜，C〜0〜-C〜8〜芳烷基，C〜3〜C〜12〜环烷基和杂环基。该化合物是可溶性环氧化物水解酶（sEH）的抑制剂，可用于治疗高血压，炎症，成人呼吸窘迫综合征。糖尿病并发症;终末期肾脏疾病;雷诺氏综合症和关节炎。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号